HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 03-23-2006, 04:56 PM   #1
Unregistered
Guest
 
Posts: n/a
3s good - 6s bad. COX 2 too - a tale of fats and HER 2......

More on fats.

RB




http://annonc.oxfordjournals.org/cgi...ull/15/11/1719

Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells

ABSTRACT

.............This report shows, to the best of our knowledge for the first time, that dietary FAs previously characterized for either their breast cancer protective effect (ALA, EPA, DHA and OA) or its tumoricidal actions (GLA) significantly downregulate Her-2/neu ECD concentration and, consequently, the activation status of Her-2/neu in SK-Br3 and BT-474 human breast cancer cell lines, which contain Her-2/neu oncogene amplification. Remarkably, LA, a {omega}-6 FA with a strong tumorigenesis stimulating effect, significantly increased Her-2/neu ECD concentration. Our current results using human breast cancer cell lines are in concordance with our previous findings demonstrating that dietary lipids influence DMBA-induced experimental mammary tumorigenesis in female rats though modulation of Her-2/neu expression [11Go]. Although much remains to be learned about the ultimate molecular mechanisms of FAs in relation to Her-2/neu, the recent characterization of a molecular link between Her-2/neu and the proinflammatory prostaglandin biosynthesis catalyzed by the enzyme cyclooxigenase-2 (COX-2) suggest an original working model in which dietary FAs would regulate either the expression and/or the activation status of Her-2/neu oncogene via COX-2 [12Go–15Go]. Nonetheless, it is reasonable to suggest that some types of dietary FAs not only represent promising therapies for prevention and/or management of Her-2/neu-overexpressing breast carcinomas, but also may be even more beneficial when given in combination with novel therapies directed against Her-2/neu. We are currently investigating whether these findings will be helpful in the design of novel approaches to delay or prevent trastuzumab (HerceptinTM) resistance.
  Reply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 05:57 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter